How long?., page-4

Emailed the company today. See my email below and Jons reply.

Hi XXXX, we’ll provide an update as soon as we are able to, but in the meantimerest assured there is no impact on progress with 2591 – all the activities inpreparation for clinical trials are fully funded.

Regards, Jon

JonPilcher

CFO& Company Secretary

NeurenPharmaceuticals

jpilcher@neurenpharma.com

www.neurenpharma.com

Mobile:+61 438 422 271

Confidential - This messageis intended for the recipients named in this message only. This message and anyattachments to it may contain information that is confidential and subject tolegal privilege. If you have received this message in error, please note thatany use, disclosure, copying and distribution of the information in thismessage is prohibited. Please delete the message and notify NeurenPharmaceuticals immediately. Thank you.

From:
Sent: Wednesday, 12 February 2020 1:15 PM
To: Jon Pilcher <[email protected]>
Subject:

Hi Jon,

I note today marks 2 months since the ‘2019 year-end update and 2020 outlook’ market announcement which advised discussions had advanced to a ‘meaningful and appropriate’ level in relation to proposals received. Are you able to advise on the following?

1. Are discussions still on-going with the party or parties detailed in this market announcement?
2. Is there an end date set?

I feel the longer these discussions go on for the more it delays the process of NNZ-2591 which is going to require funding.

Kindregards,